Head to Head Analysis: Predictive Oncology (NASDAQ:POAI) versus Hims & Hers Health (NYSE:HIMS)

Predictive Oncology (NASDAQ:POAI) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for Predictive Oncology and Hims & Hers Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1	0	0	0	1.00
Hims & Hers Health	3	10	2	0	1.93

Hims & Hers Health has a consensus target price of $45.27, indicating a potential upside of 23.47%. Given Hims & Hers Health’s stronger consensus rating and higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than Predictive Oncology.

Risk & Volatility

Predictive Oncology has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.

Insider & Institutional Ownership

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 13.7% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Predictive Oncology and Hims & Hers Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-722.01%	-235.55%
Hims & Hers Health	6.05%	24.67%	9.37%

Valuation & Earnings

This table compares Predictive Oncology and Hims & Hers Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.62 million	13.24	-$12.66 million	($20.40)	-0.31
Hims & Hers Health	$1.48 billion	5.65	$126.04 million	$0.54	67.90

Hims & Hers Health has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Summary

Hims & Hers Health beats Predictive Oncology on 13 of the 14 factors compared between the two stocks.

About Predictive Oncology

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.